Chione Ltd. 13D and 13G filings for Acrivon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-10 8:34 pm Unchanged |
2024-06-30 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Chione Ltd. | 3,848,632 12.500% |
0 (Unchanged) |
Filing |
| 2024-07-10 8:29 pm Sale |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Chione Ltd. | 3,848,632 17.300% |
-7,965 (-0.21%) |
Filing |
| 2022-11-28 3:59 pm Purchase |
2022-11-17 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Chione Ltd. | 3,856,597 18.500% |
3,856,597 (New Position) |
Filing |